Dimensional Fund Advisors LP Acquires 91,679 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Dimensional Fund Advisors LP boosted its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 38.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 330,181 shares of the biopharmaceutical company's stock after buying an additional 91,679 shares during the quarter. Dimensional Fund Advisors LP owned 0.68% of Theravance Biopharma worth $2,800,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. boosted its stake in shares of Theravance Biopharma by 41.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company's stock worth $5,005,000 after acquiring an additional 163,951 shares in the last quarter. Wellington Management Group LLP raised its position in Theravance Biopharma by 68.0% during the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company's stock valued at $3,227,000 after buying an additional 116,164 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Theravance Biopharma in the 2nd quarter worth about $286,000. Russell Investments Group Ltd. lifted its stake in Theravance Biopharma by 55.7% in the 1st quarter. Russell Investments Group Ltd. now owns 45,114 shares of the biopharmaceutical company's stock worth $405,000 after acquiring an additional 16,135 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Theravance Biopharma by 6.3% during the 1st quarter. SG Americas Securities LLC now owns 209,566 shares of the biopharmaceutical company's stock worth $1,880,000 after acquiring an additional 12,460 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on TBPH shares. Leerink Partners downgraded shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. TD Cowen lowered their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating on the stock in a research report on Tuesday, August 6th. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Monday, September 16th. Leerink Partnrs downgraded Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 6th. Finally, StockNews.com downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday, August 10th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $13.75.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of the stock in a transaction on Wednesday, August 7th. The shares were purchased at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the acquisition, the insider now directly owns 9,511,150 shares of the company's stock, valued at $74,186,970. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Price Performance

Shares of TBPH opened at $8.06 on Friday. The company has a 50-day simple moving average of $8.20 and a 200-day simple moving average of $8.80. Theravance Biopharma, Inc. has a 52 week low of $7.44 and a 52 week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. The firm had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. During the same period last year, the company earned ($0.28) EPS. On average, research analysts anticipate that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.